1
|
Wickenberg M, Mercier R, Yap M, Walker J, Baker K, LaPointe P. Hsp90 inhibition leads to an increase in surface expression of multiple immunological receptors in cancer cells. Front Mol Biosci 2024; 11:1334876. [PMID: 38645275 PMCID: PMC11027010 DOI: 10.3389/fmolb.2024.1334876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 03/20/2024] [Indexed: 04/23/2024] Open
Abstract
Heat shock protein 90 (Hsp90) is a molecular chaperone important for maintaining protein homeostasis (proteostasis) in the cell. Hsp90 inhibitors are being explored as cancer therapeutics because of their ability to disrupt proteostasis. Inhibiting Hsp90 increases surface density of the immunological receptor Major Histocompatibility Complex 1 (MHC1). Here we show that this increase occurs across multiple cancer cell lines and with both cytosol-specific and pan-Hsp90 inhibitors. We demonstrate that Hsp90 inhibition also alters surface expression of both IFNGR and PD-L1, two additional immunological receptors that play a significant role in anti-tumour or anti-immune activity in the tumour microenvironment. Hsp90 also negatively regulates IFN-γ activity in cancer cells, suggesting it has a unique role in mediating the immune system's response to cancer. Our data suggests a strong link between Hsp90 activity and the pathways that govern anti-tumour immunity. This highlights the potential for the use of an Hsp90 inhibitor in combination with another currently available cancer treatment, immune checkpoint blockade therapy, which works to prevent immune evasion of cancer cells. Combination checkpoint inhibitor therapy and the use of an Hsp90 inhibitor may potentiate the therapeutic benefits of both treatments and improve prognosis for cancer patients.
Collapse
Affiliation(s)
- Madison Wickenberg
- Department of Cell Biology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Rebecca Mercier
- Department of Cell Biology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Megan Yap
- Department of Cell Biology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - John Walker
- Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Kristi Baker
- Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Paul LaPointe
- Department of Cell Biology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
2
|
LePore L, Kronfli D, Baker K, Eggleston C, Bentzen SM, Mohindra P, Vyfhuis MAL. Identifying and Addressing Nutritional Inequities and Psychosocial Needs of Cancer Patients Residing in Zip-Code Designated Food Priority Areas (FPAs). Int J Radiat Oncol Biol Phys 2023; 117:e34-e35. [PMID: 37785187 DOI: 10.1016/j.ijrobp.2023.06.723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Nutrition is an essential aspect of cancer care at all time points leading to and after definitive therapy. Yet, cancer patients who reside in FPAs may experience limited access to healthy meals, possibly affecting cancer outcomes. There is no prospective data evaluating the consequence of residing in FPAs as it relates to perceived nutritional access, psychosocial needs, or nutritional status of cancer patients before, during, and after definitive treatment. Therefore, this study aims to characterize the nutritional needs of cancer patients undergoing curative radiation treatment (RT). We hypothesize that FPA residence will correlate with perceived lack of access to healthy food as well as other unmet psychosocial cancer needs at multiple time points during care. MATERIALS/METHODS Under IRB approval, a prospective, cross-sectional analysis was done using a questionnaire consolidated from previously validated surveys assessing the nutritional and psychosocial needs of patients with curable lung, head/neck, gynecological, or gastrointestinal cancers at different time points of cancer care (pre-treatment, 1 month, 6 months, and 1 year after completion of RT). Groups were compared using Χ2 and Mann-Whitney U tests as appropriate. Binary logistic regression was used to identify predictors of healthy food access. RESULTS From May 2019 to December 2022, 320 of 434 patients completed the survey, giving a compliance rate of 74%. Twenty-six percent of patients resided in zip-code designated FPAs. Patients who lived in FPAs were more likely to self-identify as black (60.5% vs 39.5%; p<0.001), single (p<0.001), have a lower median income (p<0.001), and were more likely to receive care at our inner-city photon therapy center (p<0.001) compared to non-FPA residents. Compared with non-FPA patients, the cohort who lived in FPAs had higher unmet nutritional needs (p = 0.003), which included a greater demand for healthier ways to eat (67.6%vs.54.4; p = 0.047) and a greater concern of having inadequate funds to buy healthy meals (44.4%vs.19.9%; p = 0.002). On MVA, marital status, median income, race, educational level and FPA residence were included, however only black race (OR:8.85; 95% CI:3.73-16.32; p<0.001) and education level (Elementary School: OR:8.32; 95% CI:1.19-58.33; p = 0.001, REF: Graduate/Professional) were predictors for nutritious meals uncertainty. CONCLUSION Inequities in nutritional needs were clearly identified in patients residing in FPAs when compared to non-FPA patients. Race and educational level are important factors in identifying patients in need of nutritional support. These demographics along with FPA-designated zip codes can be used to identify at-risk patients during clinic visits, where continuous nutritional and psychosocial support can be provided.
Collapse
Affiliation(s)
- L LePore
- University of Maryland School of Medicine, Baltimore, MD
| | - D Kronfli
- University of Maryland School of Medicine, Baltimore, MD
| | - K Baker
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - C Eggleston
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - S M Bentzen
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - P Mohindra
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD; Maryland Proton Treatment Center, Baltimore, MD
| | - M A L Vyfhuis
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD; Maryland Proton Treatment Center, Baltimore, MD
| |
Collapse
|
3
|
Allen AJ, Savla B, Datnow-Martinez C, Mendes W, Kamran SC, Ambs S, Eggleston C, Baker K, Molitoris JK, Ferris MJ, Patel AN, Rana ZH, Kunaprayoon D, Hong JJ, Davicioni E, Mishra MV, Bentzen SM, Jr WFR, Kwok Y, Vyfhuis MAL. A Precision Medicine Navigator Can Mitigate Inequities Associated with Utilization of Genomic Tests in Black Men with Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:S15-S16. [PMID: 37784380 DOI: 10.1016/j.ijrobp.2023.06.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Black men with prostate cancer in the United States experience disproportionately worse clinical outcomes compared to other racial groups. Identifying more reliable prognosticators to address these inequities has thus been the subject of considerable research scrutiny. However, prognostic genomic tools and genomic biorepositories suffer from an even greater lack of racial diversity. Strategies to mitigate these amplifying developments in inequities are desperately needed. We hypothesized that the presence of a precision medicine navigator (PMN) may mitigate inequities with standard of care (SOC) genomic test utilization among Black men with prostate cancer. MATERIALS/METHODS We retrospectively reviewed prostate cancer consults within one healthcare system from 11/2/2021 to 1/2/2022. We compared the frequency of patients who received SOC Decipher or Tempus genomic testing in the 7 months prior to the PMN start (pre-PMN) to the 7 months afterward (post-PMN). Chi square analysis was used to compare subgroups. Binary logistic regression was used to calculate the odds of receiving genomic testing. RESULTS The sample included 693 patients, 44.9% (311/693) pre-PMN and 55.1% (382/693) post-PMN, with a median age of 68 in both groups. Pre- and post-PMN racial distributions were similar with 60.1% and 60.2% White, 35.1% and 34% Black, 3.2% and 3.7% Asian/Pacific Islander, and 1.3% and 2.1% Latino, respectively. Pre- and post-PMN NCCN risk category distribution was 15.2% and 10.4% low risk, 46.8% and 49.9% intermediate risk, and 38.1% and 39.7% high risk, respectively. Pre- and post-PMN groups had 14.5% and 17% distant metastases, 77.2% and 76.9% localized disease, 10.3% and 10% prior prostatectomy, 47% and 51% income below sample median, 51% and 52% with Medicare/Medicaid, and 47% and 48% seen at community hospitals, respectively. There were no statistically significant differences for these variables pre- and post-PMN. However, from pre- to post-PMN, the proportion of Black patients receiving genomic testing increased from 19% to 58%. Black patients seen post-PMN were six times more likely to receive testing (p<0.001). Significant increases in SOC genomic testing post-PMN also occurred among lower median income patients, patients with Medicare/Medicaid, and community hospital patients. CONCLUSION The presence of a PMN may improve disparate rates of Black patients receiving SOC genomic tests for prostate cancer compared to other racial groups and may alleviate genomic testing inequities among other demographics.
Collapse
Affiliation(s)
- A J Allen
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - B Savla
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - C Datnow-Martinez
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - W Mendes
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - S C Kamran
- Massachusetts General Hospital, Boston, MA
| | - S Ambs
- Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD
| | - C Eggleston
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - K Baker
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - J K Molitoris
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - M J Ferris
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - A N Patel
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - Z H Rana
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - D Kunaprayoon
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - J J Hong
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | | | - M V Mishra
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - S M Bentzen
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD; Division of Biostatistics and Bioinformatics, University of Maryland Greenebaum Cancer Center, and Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD
| | - W F Regine Jr
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - Y Kwok
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - M A L Vyfhuis
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| |
Collapse
|
4
|
Cornista AM, Giolito MV, Baker K, Hazime H, Dufait I, Datta J, Khumukcham SS, De Ridder M, Roper J, Abreu MT, Breckpot K, Van der Jeught K. Colorectal Cancer Immunotherapy: State of the Art and Future Directions. Gastro Hep Adv 2023; 2:1103-1119. [PMID: 38098742 PMCID: PMC10721132 DOI: 10.1016/j.gastha.2023.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/17/2023]
Abstract
Cancer immunotherapy has become an indispensable mode of treatment for a multitude of solid tumor cancers. Colorectal cancer (CRC) has been one of the many cancer types to benefit from immunotherapy, especially in advanced disease where standard treatment fails to prevent recurrence or results in poor survival. The efficacy of immunotherapy in CRC has not been without challenge, as early clinical trials observed dismal responses in unselected CRC patients treated with checkpoint inhibitors. Many studies and clinical trials have since refined immunotherapies available for CRC, solidifying immunotherapy as a powerful asset for CRC treatment. This review article examines CRC immunotherapies, from their foundation, through emerging avenues for improvement, to future directions.
Collapse
Affiliation(s)
- Alyssa Mauri Cornista
- Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida
| | - Maria Virginia Giolito
- Department of Biomedical Sciences, Vrije Universiteit Brussel, Laboratory for Molecular and Cellular Therapy, Brussels, Belgium
| | - Kristi Baker
- Department of Oncology, University of Alberta, Edmonton, Canada
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada
| | - Hajar Hazime
- Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, Florida
| | - Inès Dufait
- Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - Jashodeep Datta
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida
- Division of Surgical Oncology, Dewitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida
| | - Saratchandra Singh Khumukcham
- Division of Gastroenterology, Department of Medicine, Duke University, Durham, North Carolina
- Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina
| | - Mark De Ridder
- Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
| | - Jatin Roper
- Division of Gastroenterology, Department of Medicine, Duke University, Durham, North Carolina
- Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina
| | - Maria T. Abreu
- Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, Florida
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida
| | - Karine Breckpot
- Department of Biomedical Sciences, Vrije Universiteit Brussel, Laboratory for Molecular and Cellular Therapy, Brussels, Belgium
| | - Kevin Van der Jeught
- Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida
| |
Collapse
|
5
|
Dzierlega K, Chakraborty M, Lee M, Soliman AM, Parker D, Khan S, Chan YT, Akbari M, Yokota T, Winer S, Baker K, Tsai S, Winer DA, Clemente-Casares X. Activin A-Expressing Polymorphonuclear Myeloid-Derived Suppressor Cells Infiltrate Skeletal and Cardiac Muscle and Promote Cancer Cachexia. J Immunol 2023:263858. [PMID: 37294291 DOI: 10.4049/jimmunol.2200064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Accepted: 05/18/2023] [Indexed: 06/10/2023]
Abstract
Cachexia is a major cause of death in cancer and leads to wasting of cardiac and skeletal muscle, as well as adipose tissue. Various cellular and soluble mediators have been postulated in driving cachexia; however, the specific mechanisms behind this muscle wasting remain poorly understood. In this study, we found polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) to be critical for the development of cancer-associated cachexia. Significant expansion of PMN-MDSCs was observed in the cardiac and skeletal muscles of cachectic murine models. Importantly, the depletion of this cell subset, using depleting anti-Ly6G Abs, attenuated this cachectic phenotype. To elucidate the mechanistic involvement of PMN-MDSCs in cachexia, we examined major mediators, that is, IL-6, TNF-α, and arginase 1. By employing a PMN-MDSC-specific Cre-recombinase mouse model, we showed that PMN-MDSCs were not maintained by IL-6 signaling. In addition, PMN-MDSC-mediated cardiac and skeletal muscle loss was not abrogated by deficiency in TNF-α or arginase 1. Alternatively, we found PMN-MDSCs to be critical producers of activin A in cachexia, which was noticeably elevated in cachectic murine serum. Moreover, inhibition of the activin A signaling pathway completely protected against cardiac and skeletal muscle loss. Collectively, we demonstrate that PMN-MDSCs are active producers of activin A, which in turn induces cachectic muscle loss. Targeting this immune/hormonal axis will allow the development of novel therapeutic interventions for patients afflicted with this debilitating syndrome.
Collapse
Affiliation(s)
- Kasia Dzierlega
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Mainak Chakraborty
- Division of Cellular and Molecular Biology, Diabetes Research Group, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada
| | - Megan Lee
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Amro M Soliman
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Derek Parker
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Saad Khan
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada
| | - Yi Tao Chan
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada
| | - Masoud Akbari
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Toshifumi Yokota
- Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada
| | - Shawn Winer
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
- Department of Laboratory Medicine, St. Michael's Hospital, Toronto, Ontario, Canada
| | - Kristi Baker
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Sue Tsai
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
- Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Alberta, Canada
- Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada
| | - Daniel A Winer
- Division of Cellular and Molecular Biology, Diabetes Research Group, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
- Department of Pathology, University Health Network, Toronto, Ontario, Canada
- Buck Institute for Research on Aging, Novato, CA
| | - Xavier Clemente-Casares
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
- Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Alberta, Canada
- Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
6
|
Mowat C, Dhatt J, Bhatti I, Hamie A, Baker K. Short chain fatty acids prime colorectal cancer cells to activate antitumor immunity. Front Immunol 2023; 14:1190810. [PMID: 37304266 PMCID: PMC10248408 DOI: 10.3389/fimmu.2023.1190810] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Accepted: 05/16/2023] [Indexed: 06/13/2023] Open
Abstract
Introduction Colorectal cancer (CRC) is a leading cause of death worldwide and its growth can either be promoted or inhibited by the metabolic activities of intestinal microbiota. Short chain fatty acids (SCFAs) are microbial metabolites with potent immunoregulatory properties yet there is a poor understanding of how they directly regulate immune modulating pathways within the CRC cells. Methods We used engineered CRC cell lines, primary organoid cultures, orthotopic in vivo models, and patient CRC samples to investigate how SCFA treatment of CRC cells regulates their ability to activate CD8+ T cells. Results CRC cells treated with SCFAs induced much greater activation of CD8+ T cells than untreated CRC cells. CRCs exhibiting microsatellite instability (MSI) due to inactivation of DNA mismatch repair were much more sensitive to SCFAs and induced much greater CD8+ T cell activation than chromosomally instable (CIN) CRCs with intact DNA repair, indicating a subtype-dependent response to SCFAs. This was due to SCFA-induced DNA damage that triggered upregulation of chemokine, MHCI, and antigen processing or presenting genes. This response was further potentiated by a positive feedback loop between the stimulated CRC cells and activated CD8+ T cells in the tumor microenvironment. The initiating mechanism in the CRCs was inhibition of histone deacetylation by the SCFAs that triggered genetic instability and led to an overall upregulation of genes associated with SCFA signaling and chromatin regulation. Similar gene expression patterns were found in human MSI CRC samples and in orthotopically grown MSI CRCs independent of the amount of SCFA producing bacteria in the intestine. Discussion MSI CRCs are widely known to be more immunogenic than CIN CRCs and have a much better prognosis. Our findings indicate that a greater sensitivity to microbially produced SCFAs contributes to the successful activation of CD8+ T cells by MSI CRCs, thereby identifying a mechanism that could be therapeutically targeted to improve antitumor immunity in CIN CRCs.
Collapse
Affiliation(s)
- Courtney Mowat
- Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - Jasmine Dhatt
- Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - Ilsa Bhatti
- Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - Angela Hamie
- Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - Kristi Baker
- Department of Oncology, University of Alberta, Edmonton, AB, Canada
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
7
|
Milling TJ, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, Verhamme P, Cohen AT, Beyer-Westendorf J, Michael Gibson C, Lopez-Sendon J, Crowther M, Shoamanesh A, Coppens M, Schmidt J, Albaladejo P, Connolly SJ, Bastani A, Clark C, Concha M, Cornell J, Dombrowski K, Fermann G, Fulmer J, Goldstein J, Kereiakes D, Milling T, Pallin D, Patel N, Refaai M, Rehman M, Schmaier A, Schwarz E, Shillinglaw W, Spohn M, Takata T, Venkat A, Welker J, Welsby I, Wilson J, Van Keer L, Verschuren F, Blostein M, Eikelboom J, Althaus K, Berrouschot J, Braun G, Doeppner T, Dziewas R, Genth-Zotz S, Greinacher P, Hamann F, Hanses F, Heide W, Kallmuenzer B, Kermer P, Poli S, Royl G, Schellong S, Schnupp S, Schwarze J, Spies C, Thomalla G, von Mering M, Weissenborn K, Wollenweber F, Gumbinger C, Jaschinski U, Maschke M, Mochmann HC, Pfeilschifter W, Pohlmann C, Zahn R, Bouzat P, Schmidt J, Vallejo C, Floccard B, Coppens M, van Wissen S, Arellano-Rodrigo E, Valles E, Alikhan R, Breen K, Hall R, Crowther M, Albaladejo P, Cohen A, Demchuk A, Schmidt J, Wyse D, Garcia D, Prins M, Nakamya J, Büller H, Mahaffey KW, Alexander JH, Cairns J, Hart R, Joyner C, Raskob G, Schulman S, Veltkamp R, Meeks B, Zotova E, Ahmad S, Pinto T, Baker K, Dykstra A, Holadyk-Gris I, Malvaso A, Demchuk A. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation 2023; 147:1026-1038. [PMID: 36802876 DOI: 10.1161/circulationaha.121.057844] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
BACKGROUND Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of the final analyses are presented. METHODS Patients with acute major bleeding within 18 hours of FXa inhibitor administration were enrolled. Co-primary end points were anti-FXa activity change from baseline during andexanet alfa treatment and excellent or good hemostatic efficacy, defined by a scale used in previous reversal studies, at 12 hours. The efficacy population included patients with baseline anti-FXa activity levels above predefined thresholds (≥75 ng/mL for apixaban and rivaroxaban, ≥40 ng/mL for edoxaban, and ≥0.25 IU/mL for enoxaparin; reported in the same units used for calibrators) who were adjudicated as meeting major bleeding criteria (modified International Society of Thrombosis and Haemostasis definition). The safety population included all patients. Major bleeding criteria, hemostatic efficacy, thrombotic events (stratified by occurring before or after restart of either prophylactic [ie, a lower dose, for prevention rather than treatment] or full-dose oral anticoagulation), and deaths were assessed by an independent adjudication committee. Median endogenous thrombin potential at baseline and across the follow-up period was a secondary outcome. RESULTS There were 479 patients enrolled (mean age, 78 years; 54% male, 86% White; 81% anticoagulated for atrial fibrillation at a median time of 11.4 hours since last dose, with 245 (51%) on apixaban, 176 (37%) on rivaroxaban, 36 (8%) on edoxaban, and 22 (5%) on enoxaparin. Bleeding was predominantly intracranial (n=331 [69%]) or gastrointestinal (n=109 [23%]). In evaluable apixaban patients (n=172), median anti-FXa activity decreased from 146.9 ng/mL to 10.0 ng/mL (reduction, 93% [95% CI, 94-93]); in rivaroxaban patients (n=132), it decreased from 214.6 ng/mL to 10.8 ng/mL (94% [95% CI, 95-93]); in edoxaban patients (n=28), it decreased from 121.1 ng/mL to 24.4 ng/mL (71% [95% CI, 82-65); and in enoxaparin patients (n=17), it decreased from 0.48 IU/mL to 0.11 IU/mL (75% [95% CI, 79-67]). Excellent or good hemostasis occurred in 274 of 342 evaluable patients (80% [95% CI, 75-84]). In the safety population, thrombotic events occurred in 50 patients (10%); in 16 patients, this occurred during treatment with prophylactic anticoagulation that began after the bleeding event. No thrombotic episodes occurred after oral anticoagulation restart. Specific to certain populations, reduction of anti-FXa activity from baseline to nadir significantly predicted hemostatic efficacy in patients with intracranial hemorrhage (area under the receiver operating characteristic curve, 0.62 [95% CI, 0.54-0.70]) and correlated with lower mortality in patients <75 years of age (adjusted P=0.022; unadjusted P=0.003). Median endogenous thrombin potential was within the normal range by the end of andexanet alfa bolus through 24 hours for all FXa inhibitors. CONCLUSIONS In patients with major bleeding associated with the use of FXa inhibitors, treatment with andexanet alfa reduced anti-FXa activity and was associated with good or excellent hemostatic efficacy in 80% of patients. REGISTRATION URL: https://www. CLINICALTRIALS gov; Unique identifier: NCT02329327.
Collapse
Affiliation(s)
- Truman J Milling
- Seton Dell Medical School Stroke Institute, Dell Medical School, University of Texas at Austin (T.J.M.)
| | - Saskia Middeldorp
- Department of Internal Medicine and Radboud Institute of Health Sciences, Nijmegenthe Netherlands (S.M.)
| | - Lizhen Xu
- Population Health Research Institute, McMaster University, HamiltonOntario Canada. (L.X., A.S., S.J.C.)
| | - Bruce Koch
- Alexion, AstraZeneca Rare Disease, BostonMA (B.K.)
| | - Andrew Demchuk
- Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, AlbertaCanada (A.D.)
| | - John W Eikelboom
- Department of Medicine, McMaster University, HamiltonOntario Canada. (J.W.E., M. Crowther)
| | - Peter Verhamme
- Center for Molecular and Vascular Biology, University of Leuven, Belgium (P.V.)
| | | | - Jan Beyer-Westendorf
- Department of Medicine I, Division of Hematology and Hemostasis, University Hospital Dresden, Germany (J.B-W.)
| | | | - Jose Lopez-Sendon
- Instituto de Investigación Hospital Universitario, La PazMadridSpain (J. L-S.)
| | - Mark Crowther
- Department of Medicine, McMaster University, HamiltonOntario Canada. (J.W.E., M. Crowther)
| | - Ashkan Shoamanesh
- Population Health Research Institute, McMaster University, HamiltonOntario Canada. (L.X., A.S., S.J.C.)
| | - Michiel Coppens
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands (M. Coppens)
| | - Jeannot Schmidt
- Centre Hospitalier Universitaire de Clermont-Ferrand, France (J.S.)
| | | | - Stuart J Connolly
- Population Health Research Institute, McMaster University, HamiltonOntario Canada. (L.X., A.S., S.J.C.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Keane JM, Walsh CJ, Cronin P, Baker K, Melgar S, Cotter PD, Joyce SA, Gahan CGM, Houston A, Hyland NP. Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints. Br J Cancer 2023; 128:528-536. [PMID: 36418894 PMCID: PMC9938136 DOI: 10.1038/s41416-022-02062-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 11/03/2022] [Accepted: 11/08/2022] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Distinct sets of microbes contribute to colorectal cancer (CRC) initiation and progression. Some occur due to the evolving intestinal environment but may not contribute to disease. In contrast, others may play an important role at particular times during the tumorigenic process. Here, we describe changes in the microbiota and host over the course of azoxymethane (AOM)-induced tumorigenesis. METHODS Mice were administered AOM or PBS and were euthanised 8, 12, 24 and 48 weeks later. Samples were analysed using 16S rRNA gene sequencing, UPLC-MS and qRT-PCR. RESULTS The microbiota and bile acid profile showed distinct changes at each timepoint. The inflammatory response became apparent at weeks 12 and 24. Moreover, significant correlations between individual taxa, cytokines and bile acids were detected. One co-abundance group (CAG) differed significantly between PBS- and AOM-treated mice at week 24. Correlation analysis also revealed significant associations between CAGs, bile acids and the bile acid transporter, ASBT. Aberrant crypt foci and adenomas were first detectable at weeks 24 and 48, respectively. CONCLUSION The observed changes precede host hyperplastic transformation and may represent early therapeutic targets for the prevention or management of CRC at specific timepoints in the tumorigenic process.
Collapse
Affiliation(s)
- J M Keane
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- School of Microbiology, University College Cork, Cork, Ireland
- Department of Medicine, University College Cork, Cork, Ireland
- School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland
- Department of Physiology, University College Cork, Cork, Ireland
| | - C J Walsh
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland
| | - P Cronin
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland
| | - K Baker
- Department of Medicine, University College Cork, Cork, Ireland
- Department of Pathology, University College Cork, Cork, Ireland
| | - S Melgar
- APC Microbiome Ireland, University College Cork, Cork, Ireland
| | - P D Cotter
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland
| | - S A Joyce
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland
| | - C G M Gahan
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- School of Microbiology, University College Cork, Cork, Ireland
- School of Pharmacy, University College Cork, Cork, Ireland
| | - A Houston
- APC Microbiome Ireland, University College Cork, Cork, Ireland.
- Department of Medicine, University College Cork, Cork, Ireland.
| | - N P Hyland
- APC Microbiome Ireland, University College Cork, Cork, Ireland
- Department of Physiology, University College Cork, Cork, Ireland
| |
Collapse
|
9
|
Carvajal LA, Robinson B, Kosaka Y, Jacob T, Lee J, Hood T, Baker K, Kaempf A, Amara SNA, Pucilowska J, Lind E, Tognon C, Tyner J, Kumar P, Vu T, DiMartino J. P392: PHARMACOLOGICAL INHIBITION OF SYK CONFERS ANTI-PROLIFERATIVE AND NOVEL ANTI-TUMOR IMMUNE RESPONSES IN AML. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000844456.64162.e9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
10
|
Momin A, Hermann J, Baker K, Machado A. 420 Task Related Physiology of the Dentalothalamocortical Circuit in Naïve and Stroke Rats. Neurosurgery 2022. [DOI: 10.1227/neu.0000000000001880_420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
11
|
Knight H, Jia R, Ayling K, Bradbury K, Baker K, Chalder T, Morling JR, Durrant L, Avery T, Ball JK, Barker C, Bennett R, McKeever T, Vedhara K. Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention. Public Health 2021; 201:98-107. [PMID: 34801843 PMCID: PMC8520885 DOI: 10.1016/j.puhe.2021.10.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 09/29/2021] [Accepted: 10/10/2021] [Indexed: 11/06/2022]
Abstract
OBJECTIVES Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75-90% needed to achieve population protection. Vaccine hesitancy is problematic for vaccine rollout; global reports suggest only 73% of the population may agree to being vaccinated. As a result, there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level. STUDY DESIGN & Method: We report the development of a scalable digital intervention seeking to address COVID-19 vaccine hesitancy and enhance uptake of COVID-19 vaccines in the United Kingdom. Guided by motivational interviewing (MI) principles, the intervention includes a series of therapeutic dialogues addressing 10 key concerns of vaccine-hesitant individuals. Development of the intervention occurred linearly across four stages. During stage 1, we identified common reasons for COVID-19 vaccine hesitancy through analysis of existing survey data, a rapid systematic literature review, and public engagement workshops. Stage 2 comprised qualitative interviews with medical, immunological, and public health experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 3 involved the development of therapeutic dialogues through workshops with psychological and digital behaviour change experts. Dialogues were developed to address concerns using MI principles, including embracing resistance and supporting self-efficacy. Finally, stage 4 involved digitisation of the dialogues and pilot testing with members of the public. DISCUSSION The digital intervention provides an evidence-based approach to addressing vaccine hesitancy through MI principles. The dialogues are user-selected, allowing exploration of relevant issues associated with hesitancy in a non-judgmental context. The text-based content and digital format allow for rapid modification to changing information and scalability for wider dissemination.
Collapse
Affiliation(s)
- H Knight
- University of Nottingham, School of Medicine, Nottingham, UK
| | - R Jia
- University of Nottingham, School of Medicine, Nottingham, UK
| | - K Ayling
- University of Nottingham, School of Medicine, Nottingham, UK
| | - K Bradbury
- National Institute for Health Research (NIHR) ARC Wessex, UK; University of Southampton, Department of Psychology, Southampton, UK
| | - K Baker
- National Institute for Health Research (NIHR) ARC Wessex, UK
| | - T Chalder
- Kings College London, Department of Psychological Medicine, London, UK
| | - J R Morling
- University of Nottingham, School of Medicine, Nottingham, UK; National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
| | - L Durrant
- University of Nottingham, School of Medicine, Nottingham, UK
| | - T Avery
- University of Nottingham, School of Medicine, Nottingham, UK
| | - J K Ball
- University of Nottingham, School of Life Sciences, Nottingham, UK
| | - C Barker
- National Institute for Health Research (NIHR) ARC Wessex, UK
| | | | - T McKeever
- University of Nottingham, School of Medicine, Nottingham, UK
| | - K Vedhara
- University of Nottingham, School of Medicine, Nottingham, UK.
| |
Collapse
|
12
|
Bakewell Z, Wilkinson A, Todd F, Okocha M, Baker K, McCarthy K. 837 High Prevalence of Anaemia and Mortality in Older Patients Undergoing Emergency Laparotomy. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Aim
Anaemia affects 1in10 elderly (>65) patients with a myriad of causes. Elderly patients undergoing emergency laparotomy often present with anaemia. Little is known however about the prevalence of anaemia in older people who require emergency laparotomy and the influence it may have on their outcomes.
Method
Elderly patients (>65-years old) undergoing an emergency laparotomy between May2016-November2018 in a tertiary trauma centre were prospectively identified. Data included patient demographics, haemoglobin, MCV and ferritin, blood transfusions and iron products administered, readmissions and mortality.
Results
231 patients underwent emergency laparotomy. Prevalence of pre-operative anaemia in this group was 43%. 5% were very-anaemic and 38% mildly-anaemic. Ferritin was checked within 89 patients; insufficient levels were present in 20%. 31% of all patients were given blood in the peri-operative period. 100% of patients discharged, were anaemic. For pre-operative anaemic vs non-anaemic patients, ASA grade was higher (4 vs 3), readmission rate was 19% vs 18%, 30-day mortality was 18% vs 14% and 1-year mortality rate high(34% vs 22%, p < 0.05). Very-anaemic patients (92%) received peri-operative blood compared to (41%) of mildly-anaemic patients. 30-day mortality was 0 vs 21% in very-anaemic vs mildly-anaemic patients. Mortality was 45.8% in patients who received transfusions compared to those who did not 19.9% (P < 0.0001).
Conclusions
The prevalence of anaemia in older patients undergoing emergency laparotomy is high and related to significantly increased mortality(12 months after surgery). We have identified a high-risk group of older patients with mild anaemia on presentation who may be at increased risk of mortality 3months after surgery.
Collapse
Affiliation(s)
- Z Bakewell
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - A Wilkinson
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - F Todd
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - M Okocha
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - K Baker
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| | - K McCarthy
- General Surgery, Southmead Hospital, Bristol, United Kingdom
| |
Collapse
|
13
|
Mowat C, Mosley SR, Namdar A, Schiller D, Baker K. Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10. J Exp Med 2021; 218:e20210108. [PMID: 34297038 PMCID: PMC8313406 DOI: 10.1084/jem.20210108] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Revised: 05/19/2021] [Accepted: 06/29/2021] [Indexed: 12/16/2022] Open
Abstract
Colorectal cancers (CRCs) deficient in DNA mismatch repair (dMMR) contain abundant CD8+ tumor-infiltrating lymphocytes (TILs) responding to the abundant neoantigens from their unstable genomes. Priming of such tumor-targeted TILs first requires recruitment of CD8+ T cells into the tumors, implying that this is an essential prerequisite of successful dMMR anti-tumor immunity. We have discovered that selective recruitment and activation of systemic CD8+ T cells into dMMR CRCs strictly depend on overexpression of CCL5 and CXCL10 due to endogenous activation of cGAS/STING and type I IFN signaling by damaged DNA. TIL infiltration into orthotopic dMMR CRCs is neoantigen-independent and followed by induction of a resident memory-like phenotype key to the anti-tumor response. CCL5 and CXCL10 could be up-regulated by common chemotherapies in all CRCs, indicating that facilitating CD8+ T cell recruitment underlies their efficacy. Induction of CCL5 and CXCL10 thus represents a tractable therapeutic strategy to induce TIL recruitment into CRCs, where local priming can be maximized even in neoantigen-poor CRCs.
Collapse
Affiliation(s)
- Courtney Mowat
- Department of Oncology, University of Alberta, Edmonton, Canada
| | | | - Afshin Namdar
- Department of Oncology, University of Alberta, Edmonton, Canada
| | - Daniel Schiller
- Department of Surgery, Royal Alexandra Hospital, Edmonton, Canada
| | - Kristi Baker
- Department of Oncology, University of Alberta, Edmonton, Canada
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada
| |
Collapse
|
14
|
Huffman B, Budde G, Chao J, Dayyani F, Hanna D, Botta G, Krinshpun S, Sharma S, Aushev V, Farmer T, Pela H, Tavallai M, Goodman M, Baker K, Drummond B, Aleshin A, Kasi P, Klempner S. 1415P Performance of a tumor-informed circulating tumor DNA assay from over 250 patients with over 600 plasma time points in esophageal and gastric cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
15
|
Hubbard JJ, Pyzik M, Rath T, Kozicky LK, Sand KMK, Gandhi AK, Grevys A, Foss S, Menzies SC, Glickman JN, Fiebiger E, Roopenian DC, Sandlie I, Andersen JT, Sly LM, Baker K, Blumberg RS. FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity. J Exp Med 2021; 217:151942. [PMID: 32658257 PMCID: PMC7537387 DOI: 10.1084/jem.20200359] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Revised: 04/21/2020] [Accepted: 05/29/2020] [Indexed: 12/18/2022] Open
Abstract
IgG immune complexes (ICs) promote autoimmunity through binding fragment crystallizable (Fc) γ-receptors (FcγRs). Of these, the highly prevalent FcγRIIa (CD32a) histidine (H)-131 variant (CD32aH) is strongly linked to human autoimmune diseases through unclear mechanisms. We show that, relative to the CD32a arginine (R)-131 (CD32aR) variant, CD32aH more avidly bound human (h) IgG1 IC and formed a ternary complex with the neonatal Fc receptor (FcRn) under acidic conditions. In primary human and mouse cells, both CD32a variants required FcRn to induce innate and adaptive immune responses to hIgG1 ICs, which were augmented in the setting of CD32aH. Conversely, FcRn induced responses to IgG IC independently of classical FcγR, but optimal responses required FcRn and FcγR. Finally, FcRn blockade decreased inflammation in a rheumatoid arthritis model without reducing circulating autoantibody levels, providing support for FcRn’s direct role in IgG IC-associated inflammation. Thus, CD32a and FcRn coregulate IgG IC-mediated immunity in a manner favoring the CD32aH variant, providing a novel mechanism for its disease association.
Collapse
Affiliation(s)
- Jonathan J Hubbard
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.,Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Michal Pyzik
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Timo Rath
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Lisa K Kozicky
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Kine M K Sand
- Department of Biosciences, Centre for Immune Regulation, University of Oslo, Oslo, Norway.,Department of Immunology, Centre for Immune Regulation, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway.,Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Amit K Gandhi
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Algirdas Grevys
- Department of Biosciences, Centre for Immune Regulation, University of Oslo, Oslo, Norway.,Department of Immunology, Centre for Immune Regulation, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway.,Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Stian Foss
- Department of Biosciences, Centre for Immune Regulation, University of Oslo, Oslo, Norway.,Department of Immunology, Centre for Immune Regulation, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway.,Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Susan C Menzies
- Division of Gastroenterology, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jonathan N Glickman
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Edda Fiebiger
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | | | - Inger Sandlie
- Department of Biosciences, Centre for Immune Regulation, University of Oslo, Oslo, Norway.,Department of Immunology, Centre for Immune Regulation, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway.,Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Jan Terje Andersen
- Department of Biosciences, Centre for Immune Regulation, University of Oslo, Oslo, Norway.,Department of Immunology, Centre for Immune Regulation, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway.,Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Laura M Sly
- Division of Gastroenterology, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada
| | - Kristi Baker
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Richard S Blumberg
- Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.,Harvard Digestive Diseases Center, Boston, MA
| |
Collapse
|
16
|
Zylstra AB, Kritcher AL, Hurricane OA, Callahan DA, Baker K, Braun T, Casey DT, Clark D, Clark K, Döppner T, Divol L, Hinkel DE, Hohenberger M, Kong C, Landen OL, Nikroo A, Pak A, Patel P, Ralph JE, Rice N, Tommasini R, Schoff M, Stadermann M, Strozzi D, Weber C, Young C, Wild C, Town RPJ, Edwards MJ. Record Energetics for an Inertial Fusion Implosion at NIF. Phys Rev Lett 2021; 126:025001. [PMID: 33512226 DOI: 10.1103/physrevlett.126.025001] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Revised: 10/27/2020] [Accepted: 12/10/2020] [Indexed: 06/12/2023]
Abstract
Inertial confinement fusion seeks to create burning plasma conditions in a spherical capsule implosion, which requires efficiently absorbing the driver energy in the capsule, transferring that energy into kinetic energy of the imploding DT fuel and then into internal energy of the fuel at stagnation. We report new implosions conducted on the National Ignition Facility (NIF) with several improvements on recent work [Phys. Rev. Lett. 120, 245003 (2018)PRLTAO0031-900710.1103/PhysRevLett.120.245003; Phys. Rev. E 102, 023210 (2020)PRESCM2470-004510.1103/PhysRevE.102.023210]: larger capsules, thicker fuel layers to mitigate fuel-ablator mix, and new symmetry control via cross-beam energy transfer; at modest velocities, these experiments achieve record values for the implosion energetics figures of merit as well as fusion yield for a NIF experiment.
Collapse
Affiliation(s)
- A B Zylstra
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A L Kritcher
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O A Hurricane
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D A Callahan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Baker
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Braun
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D T Casey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Clark
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Clark
- General Atomics, San Diego, California 92121, USA
| | - T Döppner
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L Divol
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D E Hinkel
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Hohenberger
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Kong
- General Atomics, San Diego, California 92121, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Nikroo
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Pak
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - P Patel
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J E Ralph
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - N Rice
- General Atomics, San Diego, California 92121, USA
| | - R Tommasini
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Schoff
- General Atomics, San Diego, California 92121, USA
| | - M Stadermann
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Strozzi
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Weber
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Young
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Wild
- Diamond Materials Gmbh, 79108 Freiburg, Germany
| | - R P J Town
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M J Edwards
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| |
Collapse
|
17
|
Casey DT, MacGowan BJ, Sater JD, Zylstra AB, Landen OL, Milovich J, Hurricane OA, Kritcher AL, Hohenberger M, Baker K, Le Pape S, Döppner T, Weber C, Huang H, Kong C, Biener J, Young CV, Haan S, Nora RC, Ross S, Robey H, Stadermann M, Nikroo A, Callahan DA, Bionta RM, Hahn KD, Moore AS, Schlossberg D, Bruhn M, Sequoia K, Rice N, Farrell M, Wild C. Evidence of Three-Dimensional Asymmetries Seeded by High-Density Carbon-Ablator Nonuniformity in Experiments at the National Ignition Facility. Phys Rev Lett 2021; 126:025002. [PMID: 33512229 DOI: 10.1103/physrevlett.126.025002] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 10/22/2020] [Accepted: 11/30/2020] [Indexed: 06/12/2023]
Abstract
Inertial confinement fusion implosions must achieve high in-flight shell velocity, sufficient energy coupling between the hot spot and imploding shell, and high areal density (ρR=∫ρdr) at stagnation. Asymmetries in ρR degrade the coupling of shell kinetic energy to the hot spot and reduce the confinement of that energy. We present the first evidence that nonuniformity in the ablator shell thickness (∼0.5% of the total thickness) in high-density carbon experiments is a significant cause for observed 3D ρR asymmetries at the National Ignition Facility. These shell-thickness nonuniformities have significantly impacted some recent experiments leading to ρR asymmetries on the order of ∼25% of the average ρR and hot spot velocities of ∼100 km/s. This work reveals the origin of a significant implosion performance degradation in ignition experiments and places stringent new requirements on capsule thickness metrology and symmetry.
Collapse
Affiliation(s)
- D T Casey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B J MacGowan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J D Sater
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A B Zylstra
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Milovich
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O A Hurricane
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A L Kritcher
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Hohenberger
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Baker
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Le Pape
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Döppner
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Weber
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - H Huang
- General Atomics, San Diego, California 92186, USA
| | - C Kong
- General Atomics, San Diego, California 92186, USA
| | - J Biener
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C V Young
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Haan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R C Nora
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Ross
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - H Robey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Stadermann
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Nikroo
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D A Callahan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R M Bionta
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K D Hahn
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A S Moore
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Schlossberg
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Bruhn
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Sequoia
- General Atomics, San Diego, California 92186, USA
| | - N Rice
- General Atomics, San Diego, California 92186, USA
| | - M Farrell
- General Atomics, San Diego, California 92186, USA
| | - C Wild
- Diamond Materials, 79108 Freiburg, Germany
| |
Collapse
|
18
|
Haskins C, Kronfli D, Lievers A, Waldo L, Baker K, Bentzen S, Mohindra P, Vyfhuis M. Characterizing Definitively Treated Cancer Patients Living Within Food Priority Areas (FPAs) to Find Predictors of Perceived Access to Healthy Meals. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Moore AS, Meezan NB, Milovich J, Johnson S, Heredia R, Baumann TF, Biener M, Bhandarkar SD, Chen H, Divol L, Izumi N, Nikroo A, Baker K, Jones O, Landen OL, Hsing WW, Moody JD, Thomas CA, Lahmann B, Williams J, Alfonso N, Schoff ME. Foam-lined hohlraum, inertial confinement fusion experiments on the National Ignition Facility. Phys Rev E 2020; 102:051201. [PMID: 33327093 DOI: 10.1103/physreve.102.051201] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 10/30/2020] [Indexed: 11/07/2022]
Abstract
Experiments on the National Ignition Facility (NIF) to study hohlraums lined with a 20-mg/cc 400-μm-thick Ta_{2}O_{5} aerogel at full scale (hohlraum diameter = 6.72 mm) are reported. Driven with a 1.6-MJ, 450-TW laser pulse, the performance of the foam liner is diagnosed using implosion hot-spot symmetry measurements of the high-density carbon (HDC) capsule and measurement of inner beam propagation through a thin-wall 8-μm Au window in the hohlraum. Results show an improved capsule performance due to laser energy deposition further inside the hohlraum, leading to a modest increase in x-ray drive and reduced preheat due to changes in the x-ray spectrum when the foam liner is included. In addition, the outer cone bubble uniformity is improved, but the predicted improvement in inner beam propagation to improve symmetry control is not realized for this foam thickness and density.
Collapse
Affiliation(s)
- A S Moore
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - N B Meezan
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - J Milovich
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - S Johnson
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - R Heredia
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - T F Baumann
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - M Biener
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - S D Bhandarkar
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - H Chen
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - L Divol
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - N Izumi
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - A Nikroo
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - K Baker
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - O Jones
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - W W Hsing
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - J D Moody
- Lawrence Livermore National Laboratory, P.O. Box 808, Livermore, California 94551-0808, USA
| | - C A Thomas
- Laboratory for Laser Energetics, University of Rochester, Rochester, New York 14623, USA
| | - B Lahmann
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Williams
- General Atomics, San Diego, California 92121, USA
| | - N Alfonso
- General Atomics, San Diego, California 92121, USA
| | - M E Schoff
- General Atomics, San Diego, California 92121, USA
| |
Collapse
|
20
|
Jeanmonod R, Rammohan G, Grimaldi M, Minor M, Stankewicz H, Patterson R, Pester J, Baker K, Melanson S, Jeanmonod D. 299 Pediatric Airway Procedures Skill Retention with Standard Simulation, the Peyton Method, or Self-Directed Learning. Ann Emerg Med 2020. [DOI: 10.1016/j.annemergmed.2020.09.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Doane MP, Morris MM, Papudeshi B, Allen L, Pande D, Haggerty JM, Johri S, Turnlund AC, Peterson M, Kacev D, Nosal A, Ramirez D, Hovel K, Ledbetter J, Alker A, Avalos J, Baker K, Bhide S, Billings E, Byrum S, Clemens M, Demery AJ, Lima LFO, Gomez O, Gutierrez O, Hinton S, Kieu D, Kim A, Loaiza R, Martinez A, McGhee J, Nguyen K, Parlan S, Pham A, Price-Waldman R, Edwards RA, Dinsdale EA. The skin microbiome of elasmobranchs follows phylosymbiosis, but in teleost fishes, the microbiomes converge. Microbiome 2020; 8:93. [PMID: 32534596 PMCID: PMC7293782 DOI: 10.1186/s40168-020-00840-x] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 04/15/2020] [Indexed: 05/16/2023]
Abstract
BACKGROUND The vertebrate clade diverged into Chondrichthyes (sharks, rays, and chimeras) and Osteichthyes fishes (bony fishes) approximately 420 mya, with each group accumulating vast anatomical and physiological differences, including skin properties. The skin of Chondrichthyes fishes is covered in dermal denticles, whereas Osteichthyes fishes are covered in scales and are mucous rich. The divergence time among these two fish groups is hypothesized to result in predictable variation among symbionts. Here, using shotgun metagenomics, we test if patterns of diversity in the skin surface microbiome across the two fish clades match predictions made by phylosymbiosis theory. We hypothesize (1) the skin microbiome will be host and clade-specific, (2) evolutionary difference in elasmobranch and teleost will correspond with a concomitant increase in host-microbiome dissimilarity, and (3) the skin structure of the two groups will affect the taxonomic and functional composition of the microbiomes. RESULTS We show that the taxonomic and functional composition of the microbiomes is host-specific. Teleost fish had lower average microbiome within clade similarity compared to among clade comparison, but their composition is not different among clade in a null based model. Elasmobranch's average similarity within clade was not different than across clade and not different in a null based model of comparison. In the comparison of host distance with microbiome distance, we found that the taxonomic composition of the microbiome was related to host distance for the elasmobranchs, but not the teleost fishes. In comparison, the gene function composition was not related to the host-organism distance for elasmobranchs but was negatively correlated with host distance for teleost fishes. CONCLUSION Our results show the patterns of phylosymbiosis are not consistent across both fish clades, with the elasmobranchs showing phylosymbiosis, while the teleost fish are not. The discrepancy may be linked to alternative processes underpinning microbiome assemblage, including possible historical host-microbiome evolution of the elasmobranchs and convergent evolution in the teleost which filter specific microbial groups. Our comparison of the microbiomes among fishes represents an investigation into the microbial relationships of the oldest divergence of extant vertebrate hosts and reveals that microbial relationships are not consistent across evolutionary timescales. Video abstract.
Collapse
Affiliation(s)
- Michael P Doane
- Sydney Institute of Marine Science, Mosman, NSW, Australia
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Megan M Morris
- Biology Department, San Diego State University, San Diego, CA, USA
- Department Biology, Stanford University, Stanford, California, USA
| | - Bhavya Papudeshi
- National Center for Genome Analysis Support, Indiana University, San Diego, Indiana, USA
| | - Lauren Allen
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Dnyanada Pande
- Computer Sciences Department, San Diego State University, San Diego, CA, USA
| | - John M Haggerty
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Shaili Johri
- Biology Department, San Diego State University, San Diego, CA, USA
- Hopkins Marine Station, Stanford University, Pacific Grove, CA, USA
| | - Abigail C Turnlund
- Biology Department, San Diego State University, San Diego, CA, USA
- Australian Centre for Ecogenomics, The University of Queensland, St. Lucia, Queens, USA
| | | | - Dovi Kacev
- Scripps Institute of Oceanography, University of California-San Diego, La Jolla, California, USA
| | - Andy Nosal
- Scripps Institute of Oceanography, University of California-San Diego, La Jolla, California, USA
- Department of Environmental and Ocean Sciences, University of San Diego, San Diego, CA, USA
| | - Deni Ramirez
- Whale Shark Mexico, ConCiencia Mexico AC, La Paz, BC, USA
| | - Kevin Hovel
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Julia Ledbetter
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Amanda Alker
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Jackeline Avalos
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Kristi Baker
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Shruti Bhide
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Emma Billings
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Steven Byrum
- Department of Biology, University of Florida, Gainesville, FL, USA
| | - Molly Clemens
- Biology Department, San Diego State University, San Diego, CA, USA
| | | | | | - Oscar Gomez
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Omar Gutierrez
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Selena Hinton
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Donald Kieu
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Angie Kim
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Rebeca Loaiza
- Biology Department, San Diego State University, San Diego, CA, USA
| | | | - Jordan McGhee
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Kristine Nguyen
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Sabrina Parlan
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Amanda Pham
- Biology Department, San Diego State University, San Diego, CA, USA
| | - Rosalyn Price-Waldman
- Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA
| | - Robert A Edwards
- Biology Department, San Diego State University, San Diego, CA, USA
- Viral Information Institute, San Diego State University, San Diego, CA, USA
| | - Elizabeth A Dinsdale
- Biology Department, San Diego State University, San Diego, CA, USA.
- Viral Information Institute, San Diego State University, San Diego, CA, USA.
| |
Collapse
|
22
|
Kilbride C, Scott D, Butcher T, Warland A, Ryan J, Norris M, Baker K, Anoyke N, Buxarrais GS, Athanasiou D, Nowicky A. Rehabilitation via home based gaming exercise for the upper-limb post stroke (RHOMBUS): results of an intervention feasibility trial. Physiotherapy 2020. [DOI: 10.1016/j.physio.2020.03.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
23
|
Kwak P, Wesolowoski M, Baker K, Joyce C, Lowery E. Use of Cyclosporine Leads to Poorer Outcomes in Patients with Cystic Fibrosis Following Lung Transplant. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
24
|
O'Brien S, Garvey P, Baker K, Brennan M, Cormican M, Cuddihy J, De Lappe N, Ellard R, Fallon Ú, Irvine N, Murphy S, O'Brien D, O'Connor M, O'Hare C, O'Sullivan MB, Part AM, Rooney P, Ryan A, Waldron G, Ward M, McKeown PJ. Investigation of a foodborne outbreak of Shigella sonnei in Ireland and Northern Ireland, December 2016: the benefits of cross-border collaboration and commercial sales data. Public Health 2020; 182:19-25. [PMID: 32120067 DOI: 10.1016/j.puhe.2020.01.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 12/11/2019] [Accepted: 01/09/2020] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To describe a cross-border foodborne outbreak of Shigella sonnei that occurred in Ireland and Northern Ireland (NI) in December 2016 whilst also highlighting the valuable roles of sales data and international collaboration in the investigation and control of this outbreak. STUDY DESIGN A cross-border outbreak control team was established to investigate the outbreak. METHODS Epidemiological, microbiological, and environmental investigations were undertaken. Traditional analytical epidemiological studies were not feasible in this investigation. The restaurant chain provided sales data, which allowed assessment of a possible increased risk of illness associated with exposure to a particular type of heated food product (product A). RESULTS Confirmed cases demonstrated sole trimethoprim resistance: an atypical antibiogram for Shigella isolates in Ireland. Early communication and the sharing of information within the outbreak control team facilitated the early detection of the international dimension of this outbreak. A joint international alert using the European Centre for Disease Control's confidential Epidemic Intelligence Information System for Food- and Waterborne Diseases and Zoonoses (EPIS-FWD) did not reveal further cases outside of the island of Ireland. The outbreak investigation identified that nine of thirteen primary case individuals had consumed product A from one of multiple branches of a restaurant chain located throughout the island of Ireland. Product A was made specifically for this chain in a food production facility in NI. S. sonnei was not detected in food samples from the food production facility. Strong statistical associations were observed between visiting a branch of this restaurant chain between 5 and 9 December 2016 and eating product A and developing shigellosis. CONCLUSIONS This outbreak investigation highlights the importance of international collaboration in the efficient identification of cross-border foodborne outbreaks and the value of using sales data as the analytical component of such studies.
Collapse
Affiliation(s)
- S O'Brien
- HSE-Health Protection Surveillance Centre, Dublin, Ireland; Department of Public Health HSE-NW, Sligo, Ireland.
| | - P Garvey
- HSE-Health Protection Surveillance Centre, Dublin, Ireland
| | - K Baker
- Food Standards Agency Northern Ireland, Belfast, Northern Ireland, Ireland
| | - M Brennan
- Food Safety Authority of Ireland, Dublin, Ireland
| | - M Cormican
- National Salmonella, Shigella and Listeria Reference Laboratory, Galway, Ireland
| | - J Cuddihy
- Department of Public Health HSE-SE, Kilkenny, Ireland
| | - N De Lappe
- National Salmonella, Shigella and Listeria Reference Laboratory, Galway, Ireland
| | - R Ellard
- Food Safety Authority of Ireland, Dublin, Ireland
| | - Ú Fallon
- Department of Public Health HSE-Midlands, Co Offaly, Ireland
| | - N Irvine
- Public Health Agency Northern Ireland, Belfast, Northern Ireland, UK
| | - S Murphy
- Environmental Health Department, Newry, Mourne & Down District Council, Northern Ireland, UK
| | - D O'Brien
- HSE Environmental Health Service Dublin Specialist Section, Dublin, Ireland
| | - M O'Connor
- Department of Public Health HSE-E, Dublin, Ireland
| | - C O'Hare
- Department of Public Health HSE-SE, Kilkenny, Ireland
| | | | - A M Part
- HSE Environmental Health Service Dublin Mid Leinster, Dublin, Ireland
| | - P Rooney
- Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK
| | - A Ryan
- Department of Public Health HSE-NW, Sligo, Ireland
| | - G Waldron
- Public Health Agency Northern Ireland, Belfast, Northern Ireland, UK
| | - M Ward
- Department of Public Health HSE-E, Dublin, Ireland
| | - P J McKeown
- HSE-Health Protection Surveillance Centre, Dublin, Ireland
| | | |
Collapse
|
25
|
Gomes F, Baker K, Woods J, Bruce J, Eaton M, Higham P, Cove-Smith L, Garbett A, Cree A, Ng C, Blackhall F, Bayman N. MA19.09 Assessing Clinical Frailty in Advanced Lung Cancer Patients - An Opportunity to Improve Patient Outcomes? J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.661] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Lindsay C, Rafee S, Nicola P, Wallace A, Burghel G, Schlecht H, Baker K, Baker E, Priest L, Rogan J, Moghadam S, Carter M, Newman W, Blackhall F. MA25.08 Characterisation of Tumor Aetiology Using Mutational Signatures from the Non-Small Cell Lung Cancer Genome. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Newell M, Mackey JR, Bigras G, Alvarez-Camacho M, Goruk S, Ghosh S, Schmidt A, Miede D, Chisotti A, Postovit L, Baker K, Mazurak V, Courneya K, Berendt R, Dong WF, Wood G, Basi SK, Joy AA, King K, Meza-Junco J, Zhu X, Field C. Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial. BMJ Open 2019; 9:e030502. [PMID: 31530611 PMCID: PMC6756327 DOI: 10.1136/bmjopen-2019-030502] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
INTRODUCTION Neoadjuvant chemotherapy for breast cancer treatment is prescribed to facilitate surgery and provide confirmation of drug-sensitive disease, and the achievement of pathological complete response (pCR) predicts improved long-term outcomes. Docosahexaenoic acid (DHA) has been shown to reduce tumour growth in preclinical models when combined with chemotherapy and is known to beneficially modulate systemic immune function. The purpose of this trial is to investigate the benefit of DHA supplementation in combination with neoadjuvant chemotherapy in patients with breast cancer. METHODS AND ANALYSIS This is a double-blind, phase II, randomised controlled trial of 52 women prescribed neoadjuvant chemotherapy to test if DHA supplementation enhances chemotherapy efficacy. The DHA supplementation group will take 4.4 g/day DHA orally, and the placebo group will take an equal fat supplement of vegetable oil. The primary outcome will be change in Ki67 labelling index from prechemotherapy core needle biopsy to definitive surgical specimen. The secondary endpoints include assessment of (1) DHA plasma phospholipid content; (2) systemic immune cell types, plasma cytokines and inflammatory markers; (3) tumour markers for apoptosis and tumour infiltrating lymphocytes; (4) rate of pCR in breast and in axillary nodes; (5) frequency of grade 3 and 4 chemotherapy-associated toxicities; and (6) patient-perceived quality of life. The trial has 81% power to detect a significant between-group difference in Ki67 index with a two-sided t-test of less than 0.0497, and accounts for 10% dropout rate. ETHICS AND DISSEMINATION This study has full approval from the Health Research Ethics Board of Alberta - Cancer Committee (Protocol #: HREBA.CC-18-0381). We expect to present the findings of this study to the scientific community in peer-reviewed journals and at conferences. The results of this study will provide evidence for supplementing with DHA during neoadjuvant chemotherapy treatment for breast cancer. TRIAL REGISTRATION NUMBER NCT03831178.
Collapse
Affiliation(s)
- Marnie Newell
- Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada
| | - John R Mackey
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
- Alberta Health Services, Edmonton, Alberta, Canada
| | - Gilbert Bigras
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | | | - Susan Goruk
- Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada
| | - Sunita Ghosh
- Alberta Health Services, Edmonton, Alberta, Canada
| | | | | | - Ann Chisotti
- Alberta Health Services, Edmonton, Alberta, Canada
| | - Lynne Postovit
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Kristi Baker
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Vera Mazurak
- Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada
| | - Kerry Courneya
- Faculty of Kinesiology, Sport and Recreation, University of Alberta, Edmonton, Alberta, Canada
| | - Richard Berendt
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - Wei-Feng Dong
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - George Wood
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | | | - Anil Abraham Joy
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Karen King
- Alberta Health Services, Edmonton, Alberta, Canada
| | | | - Xiaofu Zhu
- Alberta Health Services, Edmonton, Alberta, Canada
| | - Catherine Field
- Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
28
|
Arden J, Quinn T, Wilson T, Hanna A, Baker K, Baschnagel A, Wilson G. Automated Assessment of Biomarker Expression in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients Shows Association between High CD44, c-MET, EGFR, and GLUT1 Expression with Decreased Disease-Free Survival and Overall Survival. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
Yap M, Walker JW, Baker K, Fahlman R, Orlemans E, Lapointe P. Abstract LB-187: Hsp90 inhibitor SNX-2112 enhances neoantigen presentation on the surface of tumor cells. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-lb-187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: SNX-5422 is the orally active prodrug of SNX-2112, a potent, highly selective inhibitor of heat-shock protein 90 (Hsp90) with promising anti-tumor activity in clinical trials. SNX-5422 enhanced anti-PD-1 activity in MC38 murine model. SNX-2112 affects multiple tumor pathways, including the interferon pathway and upregulates genes associated with antigen expression, and T-cell recognition, and it interferes with tumor microenvironment immunoediting associated genes.
Methods: Cells were cultured in media supplemented with 10% fetal bovine serum at 37°C, 5% CO2, and 95% humidity. The 50% effective concentration of SNX-2112 on cell viability of SkMel28, MDAMB231, SkMel2 was determined using Cell Titer-Glo® Luminescent Cell Viability Assay. Cells were treated with SNX-2112 or other anti-tumor agents, e.g., vemurafenib, to determine surface expression of MHC class I complexes by flow cytometry using MHC class I monoclonal antibody PE conjugate (Enzo-Cat# ALX-805-711R-C100) and, in parallel, induction of apoptosis by Annexin V APC.
Results: At the lowest dose of SNX-2112 required to inhibit activity of model Hsp90 clients (MAPK), a 3 to 5-fold increase in MHC class I presentation was observed in all cells lines. Treatment of MDAMB231 with SNX-2112 caused a 3-fold increase in surface expression of MHC class I complexes, loss of Hsp90 client protein activity, and increased protein ubiquitination, without change in protein levels of immunoproteasome subunits LMP2 and LMP7. Increased surface expression of MHC class I complexes, loss of Hsp90 client function, increased protein ubiquitination without affecting immunoproteasome subunits were also found in both melanoma cell lines. This suggests that upregulation of cell surface MHC class I complexes is driven by increased Hsp90 client protein turnover. SNX-2112 treatment at concentrations sufficient to increase MHC class I surface expression also resulted in a small increase in apoptosis. Interestingly, treatment of SkMel28 with vemurafenib robustly induced apoptosis without any effect on surface expression of MHC class I complexes. Analysis of surface-expressed peptides by mass spectrometry revealed a change in peptide profile after treatment with SNX-2112.
Conclusion: SNX-2112 increased surface expression of multiple MHC class I complexes. Results suggest that SNX-2112 can drive the selective surface presentation of Hsp90 client proteins on tumor cell surface and could improve recognition by T cells specific for various cancer-associated antigens derived from mutated genes, making it potential useful in immunotherapy of cancer. This effect of SNX-2112 is independent of the induction of apoptosis as agents like vemurafenib did not elicit the same effect. Ongoing studies are focused on identifying Hsp90 client-derived peptides in surface complexes and their role in anti-tumor immunity.
Citation Format: Megan Yap, John W. Walker, Kristi Baker, Richard Fahlman, Everardus Orlemans, Paul Lapointe. Hsp90 inhibitor SNX-2112 enhances neoantigen presentation on the surface of tumor cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-187.
Collapse
Affiliation(s)
- Megan Yap
- 1University of Alberta, Edmonton, Alberta, Canada
| | | | - Kristi Baker
- 1University of Alberta, Edmonton, Alberta, Canada
| | | | | | | |
Collapse
|
30
|
Otaiba SA, Baker K, Lan P, Allor J, Rivas B, Yovanoff P, Kamata A. Elementary teacher's knowledge of response to intervention implementation: a preliminary factor analysis. Ann Dyslexia 2019; 69:34-53. [PMID: 30617942 PMCID: PMC7141440 DOI: 10.1007/s11881-018-00171-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
In the USA, many states have adopted response to intervention or multi-tiered systems of supports to provide early intervention. However, there is considerable variability in how states and schools implement RTI. Teachers are responsible for using student data from RTI to inform instructional decisions for students with or at risk for dyslexia, so it is necessary to understand the knowledge they have about the structure of RTI in their individual schools. This study reviews the results of an exploratory factor analysis of a survey aimed at measuring teachers' knowledge about RTI implementation and their understanding of RTI implementation within their school. The 52-item survey was administered online to 139 general and special education teachers. The three final factors from this factor analytic work were (1) Teacher Knowledge about Tier 1 Implementation, (2) Teacher Knowledge about Leadership and School Systems, and (3) Teacher Knowledge about Data-Based Decision Making. Factor determinacy scores demonstrated that the survey had high internal consistency. On average, teachers' survey scores were higher on the first two factors and slightly lower on the third factor. Implications of the findings for teachers of students with learning disabilities, including dyslexia, and directions for future research were discussed.
Collapse
Affiliation(s)
| | - Kristi Baker
- Southern Methodist University, , 6116 N. Central Expy., Dallas, TX, 75206 Suite 301
| | - Patrick Lan
- Southern Methodist University, , 6116 N. Central Expy., Dallas, TX, 75206 Suite 1010
| | - Jill Allor
- Southern Methodist University, , 6401 Airline Rd., Dallas, TX 75205
| | - Brenna Rivas
- Southern Methodist University, , 6116 N. Central Expy., Dallas, TX, 75206 Suite 1010
| | - Paul Yovanoff
- Southern Methodist University, , 6401 Airline Rd., Dallas, TX 75205, Southern Methodist University
| | - Akihito Kamata
- Southern Methodist Univeristy, , 6116 N. Central Expy., Dallas, TX, 75206 Suite 400
| |
Collapse
|
31
|
Al Otaiba S, Rouse AG, Baker K. Elementary Grade Intervention Approaches to Treat Specific Learning Disabilities, Including Dyslexia. Lang Speech Hear Serv Sch 2018; 49:829-842. [PMID: 30458544 DOI: 10.1044/2018_lshss-dyslc-18-0022] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 04/20/2018] [Indexed: 11/09/2022] Open
Abstract
Purpose The purpose of this narrative review of the literature is to provide a description of intensive interventions for elementary grade students with dyslexia, students with learning disabilities, and students with intensive reading and writing needs. Method First, we provide a brief overview of response to intervention. Second, we explain our theoretical framework for the review. Third, we describe evidence-based interventions, which are divided into predominantly reading or writing interventions. Fourth, we explain data-based individualization for these programs based on a taxonomy of intensity, and we provide an illustrative case study. Conclusion We conclude by describing a set of links to websites and technical assistance resources that may be helpful for speech-language pathologists, teachers, and other interventionists to stay current with this research base and to lead professional learning communities.
Collapse
|
32
|
Read M, Modasia B, Fletcher A, Thompson R, Baker K, Boelaert K, Turnell A, Smith V, Mehanna H, McCabe C. PO-124 PTTG and PBF functionally interact with P53 and predict overall survival in head and neck cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
33
|
Abstract
Inflammation is a primary driver of cancer initiation and progression. However, the complex and dynamic nature of an inflammatory response make this a very difficult process to study. Organoids are a new model system where complex multicellular structures of primary cells can be grown in a 3D matrix to recapitulate the biology of the parent tissue. This experimental model offers several distinct advantages over alternatives including the ability to be genetically engineered, implanted in vivo and reliably derived from a wide variety of normal and cancerous tissue from patients. Furthermore, long-term organoid cultures reproduce many features of their source tissue, including genetic and epigenetic alterations and drug sensitivity. Perhaps most significantly, cancer organoids can be cocultured in a variety of different systems with a patients’ own immune cells, uniquely permitting the study of autologous cancer-immune cell interactions. Experiments with such systems promise to shed light on the mechanisms governing inflammation-associated cancer while also providing prognostic information on an individual patient’s responsiveness to immunotherapeutic anti-cancer drugs. Thanks to their ability to capture important features of the complex relationship between a cancer and its microenvironment, organoids are poised to become an essential tool for unraveling the mechanisms by which inflammation promotes cancer.
Collapse
Affiliation(s)
- Kristi Baker
- Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
| |
Collapse
|
34
|
Lozano NA, Lozano A, Marini V, Saranz RJ, Blumberg RS, Baker K, Agresta MF, Ponzio MF. Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. Am J Reprod Immunol 2018; 80:e12972. [PMID: 29745444 DOI: 10.1111/aji.12972] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 04/06/2018] [Indexed: 01/09/2023] Open
Abstract
PROBLEM IgG is the only antibody class, that is, actively transferred from the mother to the fetus across the placenta by an active, neonatal Fc receptor (FcRn) mediated process during pregnancy, conferring passive immunity and protection against infections to the newborn during the first months of life. Preterm infants may not receive sufficient titers of protective antibodies, as most of them are transferred only after the 34th week of gestation. Because of the great importance of this process, we investigated in a clinical setting the placental transmission of IgG antibodies in term and preterm newborns. METHOD OF STUDY This work was conducted in 85 woman and their newborns, divided into four groups according to their clinical gestational age (≤37 weeks were considered as preterm). Blood samples were collected from the mothers and their newborns' umbilical cords to analyze total serum IgG concentrations, and a subgroup of 32 placentas was analyzed by immunohistochemistry to quantify the expression of the FcRn receptor. RESULTS Total IgG levels in both mothers and neonates increased significantly through the third trimester of gestation. Regarding the newborns, in all groups, IgG levels exceeded their mother's values by a ~2.4%. A higher expression of FcRn was detected in placentas from newborns at week 36 of gestation onwards. CONCLUSION Our results obtained from clinical samples, were in line with previous descriptions in model systems and confirmed that the IgG transfer from maternal serum to the fetus is positively correlated with FcRn expression in placental tissue throughout gestation.
Collapse
Affiliation(s)
- Natalia A Lozano
- Servicio de Alergia e Inmunologia, Clínica Universitaria Reina Fabiola, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba, Córdoba, Argentina
| | - Alejandro Lozano
- Servicio de Alergia e Inmunologia, Clínica Universitaria Reina Fabiola, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba, Córdoba, Argentina
| | - Vanina Marini
- Servicio de Alergia e Inmunologia, Clínica Universitaria Reina Fabiola, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba, Córdoba, Argentina
| | - Ricardo J Saranz
- Servicio de Alergia e Inmunologia, Clínica Universitaria Reina Fabiola, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba, Córdoba, Argentina
| | - Richard S Blumberg
- Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA
| | - Kristi Baker
- Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA
| | - Maria F Agresta
- Servicio de Alergia e Inmunologia, Clínica Universitaria Reina Fabiola, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba, Córdoba, Argentina
| | - Marina F Ponzio
- Instituto de Investigaciones en Ciencias de la Salud (INICSA)-CONICET, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| |
Collapse
|
35
|
Fenemore J, Punnett G, Yorke J, Blackhall F, Baker K. Identification of support and information needs along the care pathway for patients with non-small cell lung cancer (NSCLC) receiving treatment with curative intent chemo-radiotherapy: emerging findings from the INSIGHT study. Lung Cancer 2018. [DOI: 10.1016/s0169-5002(18)30173-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
George S, Vanhoff K, Baker K, Lake L, Rolfe P, Seewald W, Emery D. Application of a coproantigen ELISA as an indicator of efficacy against multiple life stages of Fasciola hepatica infections in sheep. Vet Parasitol 2017; 246:60-69. [DOI: 10.1016/j.vetpar.2017.08.028] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2017] [Revised: 08/18/2017] [Accepted: 08/24/2017] [Indexed: 10/18/2022]
|
37
|
Fernando EH, Dicay M, Stahl M, Gordon MH, Vegso A, Baggio C, Alston L, Lopes F, Baker K, Hirota S, McKay DM, Vallance B, MacNaughton WK. A simple, cost-effective method for generating murine colonic 3D enteroids and 2D monolayers for studies of primary epithelial cell function. Am J Physiol Gastrointest Liver Physiol 2017; 313:G467-G475. [PMID: 28751424 DOI: 10.1152/ajpgi.00152.2017] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 07/20/2017] [Accepted: 07/20/2017] [Indexed: 01/31/2023]
Abstract
Cancer cell lines have been the mainstay of intestinal epithelial experimentation for decades, due primarily to their immortality and ease of culture. However, because of the inherent biological abnormalities of cancer cell lines, many cellular biologists are currently transitioning away from these models and toward more representative primary cells. This has been particularly challenging, but recent advances in the generation of intestinal organoids have brought the routine use of primary cells within reach of most epithelial biologists. Nevertheless, even with the proliferation of publications that use primary intestinal epithelial cells, there is still a considerable amount of trial and error required for laboratories to establish a consistent and reliable method to culture three-dimensional (3D) intestinal organoids and primary epithelial monolayers. We aim to minimize the time other laboratories spend troubleshooting the technique and present a standard method for culturing primary epithelial cells. Therefore, we have described our optimized, high-yield, cost-effective protocol to grow 3D murine colonoids for more than 20 passages and our detailed methods to culture these cells as confluent monolayers for at least 14 days, enabling a wide variety of potential future experiments. By supporting and expanding on the current literature of primary epithelial culture optimization and detailed use in experiments, we hope to help enable the widespread adoption of these innovative methods and allow consistency of results obtained across laboratories and institutions.NEW & NOTEWORTHY Primary intestinal epithelial monolayers are notoriously difficult to maintain culture, even with the recent advances in the field. We describe, in detail, the protocols required to maintain three-dimensional cultures of murine colonoids and passage these primary epithelial cells to confluent monolayers in a standardized, high-yield and cost-effective manner.
Collapse
Affiliation(s)
- Elizabeth H Fernando
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Michael Dicay
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Martin Stahl
- Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; and
| | - Marilyn H Gordon
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Andrew Vegso
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Cristiane Baggio
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Laurie Alston
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Fernando Lopes
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Kristi Baker
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Simon Hirota
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Derek M McKay
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada
| | - Bruce Vallance
- Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; and
| | - Wallace K MacNaughton
- Department of Physiology and Pharmacology and Gastrointestinal Research Group, University of Calgary, Calgary, Alberta, Canada;
| |
Collapse
|
38
|
Gomes F, Woolley S, Califano R, Summers Y, Baker K, Burns K, Yorke J, Blackhall F. MA 10.07 Elderly Lung Cancer Patients on Immunotherapy: Preliminary Results from the ELDERS Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.538] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Geiger C, Baker K, Redman M, Goulart B, Eaton K, Martins R, Baik C. P1.06-009 Barriers to Clinical Trial Participation in Lung Cancer Patients, a Single Institution Experience. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Hashimoto T, Yoshida K, Goto T, Yako T, Muralidharan A, Baker K, Vitek J. Thalamic responses to somatosensory input are reduced in cerebellar ataxia. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Cook M, Lachance K, Nguyen M, Redman M, Baker K, Tseng Y, Nghiem P. 365 Outcomes among Merkel cell carcinoma patients with chronic immunosuppression. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Bayramian A, Aceves S, Anklam T, Baker K, Bliss E, Boley C, Bullington A, Caird J, Chen D, Deri R, Dunne M, Erlandson A, Flowers D, Henesian M, Latkowski J, Manes K, Molander W, Moses E, Piggott T, Powers S, Rana S, Rodriguez S, Sawicki R, Schaffers K, Seppala L, Spaeth M, Sutton S, Telford S. Compact, Efficient Laser Systems Required for Laser Inertial Fusion Energy. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-313] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Bayramian
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Aceves
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - T. Anklam
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - K. Baker
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - E. Bliss
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - C. Boley
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - A. Bullington
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - J. Caird
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - D. Chen
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - R. Deri
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - M. Dunne
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - A. Erlandson
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - D. Flowers
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - M. Henesian
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - J. Latkowski
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - K. Manes
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - W. Molander
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - E. Moses
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - T. Piggott
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Powers
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Rana
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Rodriguez
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - R. Sawicki
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - K. Schaffers
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - L. Seppala
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - M. Spaeth
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Sutton
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| | - S. Telford
- Lawrence Livermore National Laboratory, 7000 East Ave., L-470, Livermore, CA 94551
| |
Collapse
|
43
|
Fuller M, Stewart M, Baker K. Knowledge and Skill Retention of a Novel Lay-Provider Trauma Training
Curriculum in Rural Peru: A Longitudinal Study. Ann Glob Health 2017. [DOI: 10.1016/j.aogh.2017.03.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
44
|
Wolf J, Lourenco A, Alpers J, Rohatgi N, Constantini C, Hollingsworth A, Grobmyer S, Pederson H, Haythem A, Polen W, Northfelt D, Morris M, Baker K, Ghosh K, Kass F, Arterbery E, Yang R, Tran Q, Letsios E, Mulpuri R, Reese DE. Abstract P1-02-08: Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-02-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- J Wolf
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - A Lourenco
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - J Alpers
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - N Rohatgi
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - C Constantini
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - A Hollingsworth
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - S Grobmyer
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - H Pederson
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - A Haythem
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - W Polen
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - D Northfelt
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - M Morris
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - K Baker
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - K Ghosh
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - F Kass
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - E Arterbery
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - R Yang
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - Q Tran
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - E Letsios
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - R Mulpuri
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| | - DE Reese
- Rhode Island Hospital; Avera Cancer Institute; Sutter Institute; Scripps; Provista Diagnostics; Mercy Women's Hospital; Cleveland Clinic; Henry Ford Health System; Summit Medical Group New Jersey; Mayo Clinic; Banner Research Institute; St. Joseph's Hospital; Sansum Clinic; St. Mary's of Michigan; Lahey Clinic
| |
Collapse
|
45
|
|
46
|
Abstract
Background: Lichen planopilaris (LPP) is believed to be a follicular variant of lichen planus that affects pilosebaceous units, mainly of the scalp. An extremely rare variant of LPP is a linear form, which follows the lines of Blaschko. Of the five previously documented cases of linear LPP, all were limited to the face. Objective: We report the case of a 34-year-old male who presented with a nonpruritic eruption on the trunk consisting of erythematous, keratotic, folliculocentric papules following Blaschko's lines. Results: Biopsy revealed lichenoid and interface dermatitis involving the basilar epidermis and hair follicles, as well as apoptotic keratinocytes, consistent with LPP. Conclusion: This represents the first documented case of LPP, following the Blaschko's lines, in a nonfacial distribution.
Collapse
Affiliation(s)
- Kristi Baker
- Department of Pathology, Division of Dermatology, SMBD-Jewish General Hospital, McGill University, Montreal, QC
| | | |
Collapse
|
47
|
Rengan R, Baker K, Salazar L, Childs J, Higgins D, Redman M, Reichow J, Disis ML. Abstract P2-11-05: Overall survival in inflammatory breast cancer patients receiving Her-2 Neu directed tumor vaccine therapy: Matched comparison with SEER registry patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-11-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Patients with inflammatory breast cancer (IBC) have a poor prognosis, primarily due to distant dissemination. Additionally, IBC patients have an increased rate of HER2 overexpression when compared to patients with non-inflammatory breast cancer. The forms the rationale for HER2 directed tumor vaccine therapy in these patients. The purpose of this study was to examine overall survival in IBC patients receiving HER2 directed tumor vaccine therapy when compared with matched control patients from the SEER Registry.
Methods
Patients with diagnosis of Stage III or IV HER2 positive IBC having completed standard initial therapy and without evidence of disease received HER2 vaccinations after being enrolled on 5 prospective clinical trials. Overall survival data were pooled and analyzed. A control group of matched IBC patients were identified by querying the SEER database from 1997-2011. The control group was identified as any individual in the database with a code for IBC. A secondary analysis comparing survival in HER2 positive IBC vs HER2 negative IBC patients was performed by querying the SEER database from 2010 onwards, the time point when the HER2 status was coded in the database. Propensity score adjustment were made to the control group to account for any imbalances between groups in measured covariates such as stage, race, age, sex, and era of enrollment and the time interval from diagnosis to enrollment on vaccine trial (median ∼2 years).
Results
A total of 37 IBC patients received HER2 directed vaccine therapy and 676 patients were identified for the SEER control group; Stage at enrollment: stage IIIB: 30 patients in the vaccine group and 639 patients in the control group; stage IIIC: 1 patient in the vaccine group and 15 patients in the control group; stage IV 6 patients in the vaccine group and 22 in the control group. The median survival of the overall population was 112 months for the vaccine group and 47 months for the control group (p=0.04). After using propensity scores to adjust the control for imbalances in measured covariates, the median survival for the overall population was 112 months for the vaccine group and 37 months for the control group (p=0.03). There was no difference in survival between HER2 positive and HER2 negative IBC patients in the control group (p=0.6).
Conclusion
These results demonstrate promising overall survival in HER2 positive IBC patients receiving HER2 directed vaccine therapy after initial therapy. Propensity matching was performed to adjust for imbalances in measured covariates and resulted in a modest decrease in survival of the control group after adjustment, suggesting that the vaccine trial group had relatively unfavorable pre-treatment characteristics. Despite these unfavorable characteristics, patients receiving vaccine had a median survival of 112 months. These results must be further confirmed in a prospective randomized trial.
Citation Format: Rengan R, Baker K, Salazar L, Childs J, Higgins D, Redman M, Reichow J, Disis ML. Overall survival in inflammatory breast cancer patients receiving Her-2 Neu directed tumor vaccine therapy: Matched comparison with SEER registry patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-11-05.
Collapse
Affiliation(s)
- R Rengan
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - K Baker
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - L Salazar
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Childs
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - D Higgins
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - M Redman
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - J Reichow
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - ML Disis
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| |
Collapse
|
48
|
Abstract
Natural systems dominated by sediment transport are notoriously difficult to forecast. This is particularly true along the ocean coastline, a region that draws considerable human attention as economic investment and infrastructure are threatened by both persistent, long-term and acute, event driven processes (i.e., sea level rise and storm damage, respectively). Forecasting the coastline's evolution over intermediate time (daily) and space (tens of meters) scales is hindered by the complexity of sediment transport and hydrodynamics, and limited access to the detailed local forcing that drives fast scale processes. Modern remote sensing systems provide an efficient, economical means to collect data within these regions. A solar-powered digital camera installation is used to capture the coast's evolution, and machine learning algorithms are implemented to extract the shoreline and estimate the daily mean intertidal coastal profile. Methods in nonlinear time series forecasting and genetic programming applied to these data corroborate that coastal morphology at these scales is predominately driven by nonlinear internal dynamics, which partially mask external forcing signatures. Results indicate that these forecasting techniques achieve nontrivial predictive skill for spatiotemporal forecast of the upper coastline profile (as much as 43% of variance in data explained for one day predictions). This analysis provides evidence that societally relevant coastline forecasts can be achieved without knowing the forcing environment or the underlying dynamical equations that govern coastline evolution.
Collapse
Affiliation(s)
- D J Grimes
- Integrative Oceanography Division, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California 92037, USA
| | - N Cortale
- Center for Marine Science, University of North Carolina Wilmington, Wilmington, North Carolina 28409, USA
| | - K Baker
- Geodynamics Group, LLC, Newport, North Carolina 28570, USA
| | - D E McNamara
- Department of Physics and Physical Oceanography, University of North Carolina Wilmington, Wilmington, North Carolina 28403, USA
| |
Collapse
|
49
|
Kiwanuka J, Ttendo S, Eromo E, Joseph S, Duan M, Haastrup A, Baker K, Firth P. Synchronous distance anesthesia education by Internet videoconference between Uganda and the United States. J Clin Anesth 2015; 27:499-503. [DOI: 10.1016/j.jclinane.2015.04.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Revised: 03/27/2015] [Accepted: 04/16/2015] [Indexed: 11/26/2022]
|
50
|
Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J Immunol 2015; 194:4595-603. [PMID: 25934922 DOI: 10.4049/jimmunol.1403014] [Citation(s) in RCA: 169] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The neonatal FcR (FcRn) belongs to the extensive and functionally divergent family of MHC molecules. Contrary to classical MHC family members, FcRn possesses little diversity and is unable to present Ags. Instead, through its capacity to bind IgG and albumin with high affinity at low pH, it regulates the serum half-lives of both of these proteins. In addition, FcRn plays an important role in immunity at mucosal and systemic sites through its ability to affect the lifespan of IgG, as well as its participation in innate and adaptive immune responses. Although the details of its biology are still emerging, the ability of FcRn to rescue albumin and IgG from early degradation represents an attractive approach to alter the plasma half-life of pharmaceuticals. We review some of the most novel aspects of FcRn biology, immune as well as nonimmune, and provide some examples of FcRn-based therapies.
Collapse
Affiliation(s)
- Michal Pyzik
- Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA 02115; Department of Medicine, Harvard Medical School, Boston, MA 02115
| | - Timo Rath
- Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA 02115; Department of Medicine, Harvard Medical School, Boston, MA 02115; Division of Gastroenterology, Department of Medicine, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nueremberg, 91054 Erlangen, Germany
| | - Wayne I Lencer
- Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115; Harvard Digestive Diseases Center, Boston, MA 02115; and Department of Pediatrics, Harvard Medical School, Boston, MA 02115
| | - Kristi Baker
- Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA 02115; Department of Medicine, Harvard Medical School, Boston, MA 02115
| | - Richard S Blumberg
- Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA 02115; Department of Medicine, Harvard Medical School, Boston, MA 02115; Harvard Digestive Diseases Center, Boston, MA 02115; and
| |
Collapse
|